COVID-19大流行期间念珠菌血症的流行病学特征
基于美国CDC Emerging Infections Program 2020年4–8月的人群监测数据,对251例念珠菌血症患者进行病例级分析,其中64例(25.5%)SARS-CoV-2阳性。合并COVID-19者更常见ICU救治、机械通气、中心静脉导管及糖皮质激素/免疫抑制剂使用,全因院内病死率62.5%对32.1%,为2倍。
要点
- 念珠菌血症患者中约四分之一合并COVID-19。
- 合并COVID-19者急性风险因素(ICU、机械通气、中心静脉导管、免疫抑制药物)更常见。
- 合并COVID-19者院内病死率更高,应保持警惕并主动预防念珠菌血症。
核心结论
- 约四分之一念珠菌血症患者合并COVID-19,后者急性风险因素更多且院内病死率更高。
研究设计与样本
- 利用CDC Emerging Infections Program 2020年4–8月人群为基础的念珠菌血症监测数据进行病例级分析,比较COVID-19阳性与阴性患者特征,采用卡方或Fisher精确检验。
主要发现
- 251例念珠菌血症患者中64例(25.5%)SARS-CoV-2阳性。
- 肝脏疾病、实体器官恶性肿瘤和既往手术在无COVID-19合并感染者中各高3倍以上。
- ICU救治、机械通气、中心静脉导管、糖皮质激素和免疫抑制剂使用在COVID-19合并感染者中各高1.3倍以上。
- 全因院内病死率在COVID-19合并感染者中为62.5%,无合并感染者中为32.1%,前者为后者2倍。
关键数值与推荐
- COVID-19阳性定义为念珠菌培养前30天内SARS-CoV-2检测阳性。
临床怎么用
- 对COVID-19住院患者应保持对念珠菌血症的警惕,并主动采取预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The COVID-19 pandemic has resulted in unprecedented healthcare challenges, and COVID-19 has been linked to secondary infections. Candidemia, a fungal healthcare-associated infection, has been described in patients hospitalized with severe COVID-19. However, studies of candidemia and COVID-19 coinfection have been limited in sample size and geographic scope. We assessed differences in patients with candidemia with and without a COVID-19 diagnosis. METHODS: We conducted a case-level analysis using population-based candidemia surveillance data collected through the Centers for Disease Control and Prevention's Emerging Infections Program during April-August 2020 to compare characteristics of candidemia patients with and without a positive test for COVID-19 in the 30 days before their Candida culture using chi-square or Fisher's exact tests. RESULTS: Of the 251 candidemia patients included, 64 (25.5%) were positive for SARS-CoV-2. Liver disease, solid-organ malignancies, and prior surgeries were each >3 times more common in patients without COVID-19 coinfection, whereas intensive care unit-level care, mechanical ventilation, having a central venous catheter, and receipt of corticosteroids and immunosuppressants were each >1.3 times more common in patients with COVID-19. All-cause in-hospital fatality was 2 times higher among those with COVID-19 (62.5%) than without (32.1%). CONCLUSIONS: One-quarter of candidemia patients had COVID-19. These patients were less likely to have certain underlying conditions and recent surgery commonly associated with candidemia and more likely to have acute risk factors linked to COVID-19 care, including immunosuppressive medications. Given the high mortality, it is important for clinicians to remain vigilant and take proactive measures to prevent candidemia in patients with COVID-19.
引用
- Seagle EE, Jackson BR, Lockhart SR, et al. The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic. Clin Infect Dis. 2022. PMID: 34145450. doi:10.1093/cid/ciab562
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。